Opinion|Videos|March 6, 2025
New Intravesical Delivery Systems and TAR-200 in NMIBC
Experts review different treatment delivery options available for the management of non–muscle-invasive bladder cancer (NMIBC), discuss the exciting developments in NMIBC with several delivery systems and agents under investigation, and provide information about TAR-200, a targeted release system utilizing continuous intravesical release of gemcitabine, including how TAR-200 is installed within the bladder.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please review different treatment delivery options available for management of NMIBC.
- It is an exciting time for NMIBC, as several delivery systems and agents are currently under investigation for treatment of NMIBC.
- To start with, please share information about TAR-200, a targeted release system that utilizes continuous intravesical release of gemcitabine.
- Describe how TAR-200 is installed within the bladder.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves first-line Zenflow system for the treatment of BPH
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5
